Journal of Neuro-Oncology

, Volume 97, Issue 3, pp 419–423

Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri

  • Benjamin M. Ellingson
  • Scott D. Rand
  • Mark G. Malkin
  • Kathleen M. Schmainda
Case Report


Diffusion-weighted magnetic resonance imaging (DWI) is a sensitive imaging biomarker for tumor cellularity. Functional diffusion maps (fDMs), which examine voxel-by-voxel changes in the apparent diffusion coefficient (ADC) calculated from serial DWIs, have previously been applied to regions of contrast-enhancement; however, application of fDMs to non-enhancing brain tumors has not been pursued. In this case study we demonstrate the utility of applying fDMs to regions of abnormal FLAIR signal intensity in a patient diagnosed with gliomatosis cerebri: a relatively rare, infiltrative, non-enhancing brain tumor. The absolute volume of hypercellularity extracted from fDMs was useful in tracking tumor growth, which correlated in time with a progressive decline in neurological status despite no change in traditional magnetic resonance images. Results of this study demonstrate the value of fDMs, applied to regions of FLAIR abnormal signal intensity, for localizing regions of hypercellularity and for monitoring overall tumor status.


Gliomatosis cerebri Functional diffusion maps Diffusion MRI Non-enhancing glioma Cancer biomarkers 


  1. 1.
    Nevin S (1938) Gliomatosis cerebri. Brain 61:170–191CrossRefGoogle Scholar
  2. 2.
    Lantos P, Bruner J Gliomatosis cerebri. In: Kleihues P, Cavanee W (eds) Pathology and genetics of tumors of the nervous system. IARC Press, Lyon, France, pp 92–93Google Scholar
  3. 3.
    Taillibert S, Chodkiewicz C, Laigle-Donadey F, Napolitano M, Cartalat-Carel S, Sanson M (2006) Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature. J Neurooncol 76:201–205CrossRefPubMedGoogle Scholar
  4. 4.
    Galanaud D, Chinot O, Nicoli F, Confort-Gouny S, Le Fur Y, Barrie-Attarian M, Ranjeva JP, Fuetès S, Viout P, Figarella-Branger D, Cozzone PJ (2003) Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. J Neurosurg 98:269–276CrossRefPubMedGoogle Scholar
  5. 5.
    Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T, Okudo T, Liang L, Ge Y, Komohara Y, Ushio Y, Takahashi M (1999) Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 9:53–60CrossRefPubMedGoogle Scholar
  6. 6.
    Lyng H, Haraldseth O, Rofstad EK (2000) Measurements of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 43:828–836CrossRefPubMedGoogle Scholar
  7. 7.
    Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, Ross BD (2000) Diffusion magnetic resonance imaging: an early surrogate marker for therapeutic efficacy in brain tumors. J Natl Cancer Inst 92:2029–2036CrossRefPubMedGoogle Scholar
  8. 8.
    Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q, Tsien CI, Mukherji S, Quint DJ, Gebarski SS, Robertson PL, Junck L, Rehemtulla A, Ross BD (2005) Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 102:5524–5529CrossRefPubMedGoogle Scholar
  9. 9.
    Moffat BA, Chenevert TL, Meyer CR, McKeever PE, Hall DE, Hoff BA, Johnson TD, Rehemtulla A, Ross BD (2006) The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 8:259–267CrossRefPubMedGoogle Scholar
  10. 10.
    Hamstra DA, Galbán CJ, Meyer CR, Johnson TD, Sundgren PC, Tsien CI, Lawrence TS, Junck L, Ross DJ, Rehemtulla A, Ross BD, Chenevert TL (2008) Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 26:3387–3394CrossRefPubMedGoogle Scholar
  11. 11.
    Hamstra DA, Chenevert TL, Moffat BA, Johnson TD, Meyer CR, Mukherji S, Quint DJ, Gebarski SS, Fan X, Tsien CI, Lawrence TS, Junck L, Rehemtulla A, Ross BD (2005) Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci USA 102:16759–16764CrossRefPubMedGoogle Scholar
  12. 12.
    Cox RW, Jesmanowicz A (1999) Real-time 3D image registration for functional MRI. Magn Reson Med 42:1014–1018CrossRefPubMedGoogle Scholar
  13. 13.
    Ellingson BM, Malkin MG, Rand SD, Hoyt A, Connelly J, Bedekar DP, Kurpad SN, Schmainda KM (2009) Comparison of cytotoxic and anti-angiogenic treatment responses using functional diffusion maps in FLAIR abnormal regions. Proc Intl Soc Magn Reson Med 17:1010Google Scholar
  14. 14.
    Ellingson BM, Malkin MG, Rand SD, Bedekar DP, Schmainda KM (2009) Functional diffusion maps applied to FLAIR abnormal areas are valuable for the clinical monitoring of recurrent brain tumors. Proc Intl Soc Magn Reson Med 17:285Google Scholar
  15. 15.
    Chamberlain MC, Murovic JA, Levin VA (1988) Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology 38:1371–1374PubMedGoogle Scholar
  16. 16.
    Barker FG II, Chang SM, Huhn SL, Davis RL, Gutin PH, McDermott MW, Wilson CB, Prados MD (1997) Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 80:936–941CrossRefPubMedGoogle Scholar
  17. 17.
    Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF (1998) The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 49:436–440CrossRefPubMedGoogle Scholar
  18. 18.
    Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA (2002) How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 59:947–949PubMedGoogle Scholar
  19. 19.
    Kondziolka D, Lunsford LD, Martinez AJ (1993) Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg 79:533–536CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Benjamin M. Ellingson
    • 1
    • 2
    • 3
  • Scott D. Rand
    • 1
    • 2
  • Mark G. Malkin
    • 1
    • 3
    • 4
  • Kathleen M. Schmainda
    • 1
    • 2
    • 5
  1. 1.Translational Brain Tumor ProgramMedical College of WisconsinMilwaukeeUSA
  2. 2.Department of RadiologyMedical College of WisconsinMilwaukeeUSA
  3. 3.Department of NeurosurgeryMedical College of WisconsinMilwaukeeUSA
  4. 4.Department of NeurologyMedical College of WisconsinMilwaukeeUSA
  5. 5.Department of BiophysicsMedical College of WisconsinMilwaukeeUSA

Personalised recommendations